Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable Differentiated Thyroid Gland Carcinoma”

9 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 9 of 9 results

Testing effectiveness (Phase 2)UnknownNCT01118065
What this trial is testing

Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer

Who this might be right for
Head and Neck Cancer
Leiden University Medical Center 42
Testing effectiveness (Phase 2)Active Not RecruitingNCT04171622
What this trial is testing

Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer

Who this might be right for
Metastatic Thyroid Gland CarcinomaPoorly Differentiated Thyroid Gland CarcinomaStage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8+3 more
M.D. Anderson Cancer Center 25
Testing effectiveness (Phase 2)Study completedNCT02973997
What this trial is testing

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

Who this might be right for
Columnar Cell Variant Thyroid Gland Papillary CarcinomaFollicular Variant Thyroid Gland Papillary CarcinomaMetastatic Thyroid Gland Follicular Carcinoma+23 more
Academic and Community Cancer Research United 57
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06848920
What this trial is testing

Study of Sinibolimab Combined with Lenvatinib As Neoadjuvant Therapy for Locally Advanced Unresectable Differentiated Thyroid Carcinoma

Who this might be right for
Differentiated Thyroid Carcinoma (DTC)Neoadjuvant Therapy
Zhejiang University 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT03181100
What this trial is testing

Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

Who this might be right for
Metastatic Thyroid Gland CarcinomaPoorly Differentiated Thyroid Gland CarcinomaStage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8+4 more
M.D. Anderson Cancer Center 50
Testing effectiveness (Phase 2)Study completedNCT01208051
What this trial is testing

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

Who this might be right for
Refractory Differentiated Thyroid Gland CarcinomaRefractory Thyroid Gland Follicular CarcinomaRefractory Thyroid Gland Hurthle Cell Carcinoma+2 more
National Cancer Institute (NCI) 127
Testing effectiveness (Phase 2)Study completedNCT00381641
What this trial is testing

Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery

Who this might be right for
Differentiated Thyroid Gland CarcinomaRecurrent Thyroid Gland CarcinomaRefractory Thyroid Gland Carcinoma+16 more
National Cancer Institute (NCI) 63
Not applicableActive Not RecruitingNCT02185560
What this trial is testing

Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib

Who this might be right for
Thyroid Carcinoma
Bayer 453
Testing effectiveness (Phase 2)Study completedNCT00784303
What this trial is testing

Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology

Who this might be right for
Thyroid Cancer
Eisai Inc. 117